Compare AstraZeneca plc (AZN) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Western Union Co — how do they compare? AstraZeneca plc trades at $157.69 (market cap $248.14B), while Western Union Co trades at $6.93 (market cap $2.20B). The key difference: AstraZeneca plc is far larger — about 112.8× Western Union Co's market cap, and Western Union Co pays the higher dividend (13.33%). Which is the better fit depends on your goals.
| AZN | WU | |
|---|---|---|
Market Cap | $248.14B | $2.20B |
Sector | Health | Technology |
52-Week High | $209.48 | $10.28 |
52-Week Low | $147.06 | $6.36 |
Enterprise Value | $275.41B | $2.10B |
Dividend Yield | 2.01% | 13.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Western Union (WU) trades at $7.03, down 0.71% on the day, with a bearish technical outlook and recent earnings misses. The stock shows low valuation multiples (P/E 5.69, P/S 0.56) and strong profitability metrics (ROE 43.97%), but revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent news highlights challenges in retail money transfers and a new digital initiative with Rain.
The investment outlook is cautious due to declining revenue, earnings volatility, and bearish analyst sentiment. Opportunities exist from deep value metrics and dividend yield, but risks include competitive pressures and execution challenges in digital transformation. The consensus price target is $7.14, suggesting limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
